SAN CARLOS, Calif.--(BUSINESS WIRE)--Nektar Therapeutics (Nasdaq:NKTR) has initiated a Phase 1 clinical trial program, evaluating the safety, tolerability and pharmacokinetics of NKTR-102 (PEG-irinotecan), an innovative new oncology therapy with the potential to treat patients with refractory solid tumors, the company announced today.
